GlobeNewswire by notified

Resolutions at Valoe’s Annual General Meeting and Organising of the Board of Directors

Share

Valoe Corporation         Stock Exchange Release         26 May 2023 at 14.40 Finnish time

Valoe Corporation's Annual General Meeting was held on 26 May 2023 in Mikkeli, Finland. The AGM approved the 2022 financial statements and discharged the members of the Board and the President and CEO from liability for the financial year 2022. According to the Board' proposal, it was resolved that no dividend for the financial year 2022 will be distributed. It was also resolved that the loss for the financial period that ended on 31 December 2022 will be entered in retained earnings. The AGM approved the remuneration report for Valoe’s governing bodies. The resolution on the remuneration report is advisory.

It was resolved that the Board of Directors will have four members. Industrial counsellor Hannu Savisalo, Ville Parpola, Tuomas Honkamäki and Iikka Savisalo continue as old Board members in the Board of Directors.

At its organizing meeting following the Annual General Meeting, Valoe's Board of Directors elected Hannu Savisalo as the Chairman and Ville Parpola as the Vice Chairman of the Board. The Board of Directors decided, due to the scope of the company's business, that it is not necessary to establish any separate Board committees.

The Annual General Meeting resolved that an annual remuneration of EUR 40,000 will be paid to the Chairman and to the Vice Chairman of the Board, and EUR 30,000 to the members of the Board of Directors. Further, travel costs will be paid to the Board members pursuant to the company’s travel policy.

In addition, the General Meeting resolved to authorize the Board of Directors to decide on option rights, pursuant to the Chapter 10, Section 1 of the Finnish Companies Act, to be given to the Directors of the Board so that, following the share subscriptions based on option rights, the number of the shares in the Company could increase by a total maximum amount of 30 million shares. The authorization may be used for a stock option scheme directed to the Directors of the Board during the financial year 2023. The authorization is in force until 31 December 2023. Based on this authorization, 15 million option rights can be given to the Chairman of the Board, and to the other Board members 7.5 million option rights per member. The subscription price for shares subscribed for based on the option rights is EUR 0.03 per share. Based on the option rights, shares can be subscribed for until 31 December 2025. The exercise of options granted to the Board of Directors based on this authorization is conditional on the company's operating cash flow being positive in the fourth quarter of the financial year 2023.

Authorised Public Accountants Moore Idman Oy was elected as the company’s auditor and KHT Antti Niemistö, Authorised Public Accountant, as the responsible auditor.

The General Meeting resolved to authorize the Board of Directors to decide on a share issue with and/or without payment, either in one or in several occasions, including right to resolve on option rights and other rights entitling to shares pursuant to the Chapter 10, Section 1 of the Finnish Companies Act so that the number of new shares issued based on the authorization or number of shares issued based on option rights and other special rights entitling to the shares pursuant to the Chapter 10, Section 1 of the Finnish companies Act, can increase by a total maximum amount of 200,000,000 shares. The authorization does not exclude the Board’s right to decide also on directed issue of shares or option rights and other special rights pursuant to the Chapter 10, Section 1 of the Finnish Companies Act. The authorization may be used for important arrangements from the company’s point of view e.g. to strengthen the capital structure, to finance investments, for acquisitions and business transactions or other business arrangements, or to expand ownership structure, or for other purposes resolved by the Board involving a weighty financial reason for issuing shares or option rights or special rights entitling to shares pursuant to the Chapter 10, Section 1 of the Finnish Companies Act. The share issue may be executed by deviating from the shareholders' pre-emptive subscription right provided the company has a weighty financial reason for that. The authorization is in force until 30 June 2024.

The General Meeting resolved to authorize the Board of Directors to decide on option rights pursuant to the Chapter 10, Section 1 of the Finnish Companies Act so that, following the share subscriptions based on option rights, the number of the shares in the Company could increase by a total maximum amount of 30 million shares. The authorization may be used for a stock option scheme directed to the company’s personnel and CEO during the financial year 2023. The Board of Directors is entitled to decide on the other terms of the option rights. The authorization is in force until 31 December 2023.

The CEO’s presentation given at the meeting will be available on the company’s website.


In Mikkeli 26 May 2023

Valoe Corporation

Board of Directors

For more information:
Iikka Savisalo, President and CEO, Valoe Corporation
Tel. +358 40 521 6082
email: iikka.savisalo@valoe.com

Distribution:
NASDAQ OMX, Helsinki
Main media
www.valoe.com

Valoe Corporation specializes in the clean energy, especially in photovoltaic solutions. Valoe provides automated production technology for solar modules based on the company’s own technology; production lines for modules; solar modules and special components for solar modules. Valoe's head office is located in Mikkeli, Finland.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Sampo plc’s share buybacks 05/06/20236.6.2023 07:30:00 CEST | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 06/06/2023 at 08:30 am Sampo plc’s share buybacks 05/06/2023 On 05/06/2023 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)7,94943.63AQEU31,84643.50CEUX13,65043.61TQEX66,55543.52XHELTOTAL120,00043.53 *rounded to two decimals On 29 March 2023, Sampo announced a share buyback programme of up to a maximum of EUR 400 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 3 April 2023, is based on the authorisation granted by Sampo's Annual General Meeting on 18 May 2022. After the disclosed transactions, the company owns in total 4,530,623 Sampo A shares representing 0.89 per cent of the total number of shares in Sampo plc. Details o

IDEX Biometrics – Disclosure of holding - 6 June 20236.6.2023 07:30:00 CEST | Press release

This notice is issued by IDEX Biometrics ASA on behalf of the shareholder mentioned below. Reference is made to the disclosure on 26 May that Robert Keith had lent 42,000,000 shares in connection with the settlement of Tranche 1 in the private placement of shares in IDEX Biometrics on 24 May 2023. The shares have been returned to Mr. Keith. After the return of the shares, Mr. Keith and close relations hold 157,873,873 shares or rights to shares or 12.3% of the total outstanding shares and votes in IDEX Biometrics, based on the share capital after completion of Tranche 1 of the private placement. This notice was published by Erling Svela, Vice president of finance, on 6 June 2023 at 07:30 CET on behalf of IDEX Biometrics ASA on behalf of Robert Keith.

Sercel Awarded Major Contract for a GPR300 Seabed Nodal Solution for Seismic Survey in China6.6.2023 07:30:00 CEST | Press release

Paris, France – June6, 2023 CGG announced today that Sercel has made a major sale of its GPR300 seabed nodal solution to Sinopec, the Chinese oil and gas exploration, refining and distribution company. Over 6,000 nodes will be deployed this month in the Bohai Sea off the east coast of mainland China. Based on Sercel’s breakthrough QuietSeis® MEMS technology, the GPR300 delivers unprecedented broadband signal sensing capability and fidelity, and ultra-quiet performance to enable best-in-class subsurface imaging and outperforms conventional OBN equipment. With its compact and lightweight design, the GPR300 is easy to use whatever the deployment mode. Emmanuelle Dubu, Sercel CEO, said: “We are very pleased to partner with Sinopec once again and to support them in successfully completing this new complex project. On the strength of our in-depth knowledge of the seismic industry and the greater opportunities we see node acquisition bringing in terms of enhanced data quality and insight for

Sleeping better starts here: participate in the webinar of Beter Bed and Dr Sleep6.6.2023 07:30:00 CEST | Press release

On 13 June, Beter Bed, in collaboration with ‘Dr Sleep’, Merijn van de Laar, will be organising a free webinar for everyone keen to improve their sleep. Anyone who sleeps badly one night will notice the difference immediately the next day in terms of mood and focus. Moreover, sleeping badly has an impact on health. As many as one in five Dutch people suffer from some form of sleep deprivation. This webinar is a perfect opportunity for many to change this immediately. The free webinar on 13 June at 8 p.m. will provide more insight into all the factors that influence the quality of sleep. The webinar aims to raise awareness of the impact of poor sleep and motivate viewers to improve sleep quality for a healthier, more energetic and happier life. Participants will learn how to put these steps into practice immediately. Dr Sleep, Merijn van de Laar, explains: “Everything about sleeping better will be dealt with. When do you sleep better, and what happens if your night's sleep is no longer

AccuStem Sciences, Inc. Announces Collaboration Agreement with University Hospitals6.6.2023 07:00:00 CEST | Press release

LONDON and PHOENIX, Ariz., June 06, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, today announced the establishment of a joint clinical collaboration agreement with University Hospitals. Per the terms of this agreement, University Hospitals will provide tissue samples with clinical outcomes to AccuStem for research purposes. The scope of the agreement covers a multitude of different cancers but will initially focus on breast cancer cases to support further validation of the StemPrintER test. The goal of the initial project is to build on the strong foundation of data for StemPrintER by demonstrating additional clinical utility beyond identifying patients’ risk of recurrence. This next step is critical for women with early stage breast cancer because there are many tests to determine the need for chemotherapy but there are no genomic tools to inform decisions earlier in the c